AbbVie 2014 Annual Report Download - page 46

Download and view the complete annual report

Please find page 46 of the 2014 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 182

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182

13NOV201221352027
The following table details the sales of key products.
Percent change
At actual At constant
currency currency
rates rates
years ended December 31 (in millions) 2014 2013 2012 2014 2013 2014 2013
HUMIRA
United States $ 6,524 $ 5,236 $ 4,377 25% 20% 25% 20%
International 6,019 5,423 4,888 11% 11% 13% 12%
Total $12,543 $10,659 $ 9,265 18% 15% 19% 15%
AndroGel
United States $ 934 $ 1,035 $ 1,152 (10)% (10)% (10)% (10)%
Kaletra
United States $ 213 $ 244 $ 279 (13)% (13)% (13)% (13)%
International 657 718 734 (9)% (2)% (5)% (1)%
Total $ 870 $ 962 $ 1,013 (10)% (5)% (7)% (4)%
Synagis
International $ 835 $ 827 $ 825 1% — 9% 9%
Lupron
United States $ 580 $ 566 $ 569 3% (1)% 3% (1)%
International 198 219 231 (10)% (5)% (5)% (3)%
Total $ 778 $ 785 $ 800 (1)% (2)% —% (1)%
Synthroid
United States $ 709 $ 622 $ 551 14% 13% 14% 13%
Sevoflurane
United States $ 83 $ 77 $ 82 7% (5)% 7% (5)%
International 467 491 520 (5)% (6)% (1)% (4)%
Total $ 550 $ 568 $ 602 (3)% (6)% —% (4)%
Creon
United States $ 516 $ 412 $ 353 25% 17% 25% 17%
Dyslipidemia products
United States $ 328 $ 1,076 $ 2,145 (70)% (50)% (70)% (50)%
Duodopa
International $ 220 $ 178 $ 149 24% 20% 25% 16%
VIEKIRA PAK
United States $ 48 — — 100% — 100% —
Other $ 1,629 $ 1,666 $ 1,525 (2)% 9% (1)% 10%
Total $19,960 $18,790 $18,380 6% 2% 8% 3%
On a constant currency basis, global HUMIRA sales increased 19 percent in 2014 and 15 percent in
2013, primarily as a result of market growth across therapeutic categories and geographies, approval of
new indications, higher market share, and favorable pricing in certain geographies. AbbVie is pursuing
several new indications to help further differentiate HUMIRA from competing products and add to the
sustainability and future growth of HUMIRA.
AndroGel sales decreased 10 percent in both 2014 and 2013 primarily due to a decline in the overall
U.S. testosterone replacement market. The company expects this trend will continue. AndroGel sales for 2013
were impacted by rebates implemented during the second half of 2012, certain account losses in early
40 2014 Form 10-K